✍️ SeungMi Lee, Partner at JNPMEDI
The Choice of a Coffee, and the Choice of Digital Healthcare
Imagine picking a menu item at a coffee shop each morning. An Americano is safe but bland, a latte is smooth but high in calories, and a new special is intriguing but risky. We choose based on our daily condition, budget, and our willingness to risk failure. The reality that healthcare startups face under the Digital Medical Products Act, enacted on January 24 this year, is quite similar. This world-first law offers innovation opportunities but also the unease of an uncharted path. It’s far more complex than choosing coffee, and the outcome directly impacts a company’s survival.
Where’s the Manual for This New Law?
When buying a new electronic device, the first thing we do is look for the manual. Even intuitive products need instructions to be fully utilized. Startups handed this "new product"—the Digital Medical Products Act—are now facing complex machinery without a manual. While the law is enacted, detailed operational guidelines are still incomplete. It’s like buying a new smartphone only to find basic instructions saying “Turn on power,” while detailed features are marked “Updates coming soon.” This creates significant stress, especially for startups without dedicated regulatory teams.
Ambiguous Boundaries and Practical Challenges
The biggest hurdle for startups is the ambiguity of boundaries. It’s often unclear whether their products fall under existing medical device laws or the new Digital Medical Products Act. Even experts are still studying the new law, and external consulting costs are proving higher than anticipated.
Not everyone is in the same boat; differences in capital and networks must be acknowledged. New challenges have emerged alongside the law’s implementation. Most urgently, startups need to internalize regulatory expertise. Capabilities in clinical trial design, Quality Management System (QMS) establishment, and cybersecurity are essential—but early-stage startups struggle to secure specialized talent, forcing reliance on external consulting that adds financial burden.
Data governance is another new barrier. Strict requirements for patient data protection demand systems and expert personnel. Moreover, the domestic market alone has limits; strategic navigation of global regulatory environments, such as U.S. FDA and European MDR is essential.
Opportunities and Practical Strategies Amid Change
These changes also impact the investment ecosystem. Venture capitalists remain positive in the long term but cautious in the short term. However, this caution does not close the door on opportunity. Instead, it creates a golden opportunity for prepared startups to secure differentiated competitive advantage. While many wait and see, those who move forward boldly are seizing the lead.
Successful startups leveraging the Digital Medical Products Act have reviewed regulatory requirements thoroughly from the product planning stage and built their business models accordingly. They have also formed strategic partnerships with hospitals, pharmaceutical companies, and regulatory specialists to create synergy. Collaboration with major hospitals to simultaneously secure clinical data and conduct real-world validation is notably increasing.
For healthcare startups preparing for a KOSDAQ listing, the Digital Medical Products Act has become pivotal. Regulatory readiness is emerging as a key evaluation criterion in IPO reviews, and recent prospectuses present specific plans and status regarding regulatory compliance. This shows investors increasingly prioritize regulatory risk when assessing long-term sustainability.
Realistic Survival Strategies and Future Turning Points
The most realistic approach for startups now is to identify which regulatory category their product falls into — and if unclear, actively utilize MFDS pre-consultation. Rather than trying to solve everything at once, a gradual approach is effective: start with what is feasible under existing guidelines and adapt as new standards are released.
Given internal resource limitations, leveraging regulatory consultants and legal experts must be considered. The initial cost may be burdensome, but it is a necessary investment to minimize trial and error. Building collaboration with medical institutions, pharmaceutical companies, and IT organizations is also essential to secure clinical data, validate products, and prepare for global expansion.
Industry experts see the next six months as a decisive period for detailed standards under the Digital Medical Products Act. How startups prepare and respond during this window will largely shape their future competitiveness.
The Wisdom of Turning Uncertainty into Opportunity
Five months after implementation, we remain in a transitional phase of both expectation and concern. Yet, uncertainty can be transformed into preparedness. Trial and error is inevitable, but the experience gained will become a competitive asset in global markets.
Now is a prime time to build a competitive advantage through proactive strategies. New growth opportunities await startups adapting boldly to change. What is needed is patience, execution, and a clear sense of purpose. Just as we know why we order a specific coffee, we must clarify why we are embarking on this journey. Only then can we move confidently toward our goals, undeterred by uncertainty.
📌 To see the original article : https://www.investnews.co.kr/news/articleView.html?idxno=3001884
✍️ SeungMi Lee, Partner at JNPMEDI
The Choice of a Coffee, and the Choice of Digital Healthcare
Imagine picking a menu item at a coffee shop each morning. An Americano is safe but bland, a latte is smooth but high in calories, and a new special is intriguing but risky. We choose based on our daily condition, budget, and our willingness to risk failure. The reality that healthcare startups face under the Digital Medical Products Act, enacted on January 24 this year, is quite similar. This world-first law offers innovation opportunities but also the unease of an uncharted path. It’s far more complex than choosing coffee, and the outcome directly impacts a company’s survival.
Where’s the Manual for This New Law?
When buying a new electronic device, the first thing we do is look for the manual. Even intuitive products need instructions to be fully utilized. Startups handed this "new product"—the Digital Medical Products Act—are now facing complex machinery without a manual. While the law is enacted, detailed operational guidelines are still incomplete. It’s like buying a new smartphone only to find basic instructions saying “Turn on power,” while detailed features are marked “Updates coming soon.” This creates significant stress, especially for startups without dedicated regulatory teams.
Ambiguous Boundaries and Practical Challenges
The biggest hurdle for startups is the ambiguity of boundaries. It’s often unclear whether their products fall under existing medical device laws or the new Digital Medical Products Act. Even experts are still studying the new law, and external consulting costs are proving higher than anticipated.
Not everyone is in the same boat; differences in capital and networks must be acknowledged. New challenges have emerged alongside the law’s implementation. Most urgently, startups need to internalize regulatory expertise. Capabilities in clinical trial design, Quality Management System (QMS) establishment, and cybersecurity are essential—but early-stage startups struggle to secure specialized talent, forcing reliance on external consulting that adds financial burden.
Data governance is another new barrier. Strict requirements for patient data protection demand systems and expert personnel. Moreover, the domestic market alone has limits; strategic navigation of global regulatory environments, such as U.S. FDA and European MDR is essential.
Opportunities and Practical Strategies Amid Change
These changes also impact the investment ecosystem. Venture capitalists remain positive in the long term but cautious in the short term. However, this caution does not close the door on opportunity. Instead, it creates a golden opportunity for prepared startups to secure differentiated competitive advantage. While many wait and see, those who move forward boldly are seizing the lead.
Successful startups leveraging the Digital Medical Products Act have reviewed regulatory requirements thoroughly from the product planning stage and built their business models accordingly. They have also formed strategic partnerships with hospitals, pharmaceutical companies, and regulatory specialists to create synergy. Collaboration with major hospitals to simultaneously secure clinical data and conduct real-world validation is notably increasing.
For healthcare startups preparing for a KOSDAQ listing, the Digital Medical Products Act has become pivotal. Regulatory readiness is emerging as a key evaluation criterion in IPO reviews, and recent prospectuses present specific plans and status regarding regulatory compliance. This shows investors increasingly prioritize regulatory risk when assessing long-term sustainability.
Realistic Survival Strategies and Future Turning Points
The most realistic approach for startups now is to identify which regulatory category their product falls into — and if unclear, actively utilize MFDS pre-consultation. Rather than trying to solve everything at once, a gradual approach is effective: start with what is feasible under existing guidelines and adapt as new standards are released.
Given internal resource limitations, leveraging regulatory consultants and legal experts must be considered. The initial cost may be burdensome, but it is a necessary investment to minimize trial and error. Building collaboration with medical institutions, pharmaceutical companies, and IT organizations is also essential to secure clinical data, validate products, and prepare for global expansion.
Industry experts see the next six months as a decisive period for detailed standards under the Digital Medical Products Act. How startups prepare and respond during this window will largely shape their future competitiveness.
The Wisdom of Turning Uncertainty into Opportunity
Five months after implementation, we remain in a transitional phase of both expectation and concern. Yet, uncertainty can be transformed into preparedness. Trial and error is inevitable, but the experience gained will become a competitive asset in global markets.
Now is a prime time to build a competitive advantage through proactive strategies. New growth opportunities await startups adapting boldly to change. What is needed is patience, execution, and a clear sense of purpose. Just as we know why we order a specific coffee, we must clarify why we are embarking on this journey. Only then can we move confidently toward our goals, undeterred by uncertainty.
📌 To see the original article : https://www.investnews.co.kr/news/articleView.html?idxno=3001884